{"id":828355,"date":"2025-03-20T18:03:43","date_gmt":"2025-03-20T22:03:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"},"modified":"2025-03-20T18:03:43","modified_gmt":"2025-03-20T22:03:43","slug":"nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","title":{"rendered":"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN FRANCISCO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 20, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference:<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg\" title=\"(PRNewsfoto\/Nektar Therapeutics)\" alt=\"(PRNewsfoto\/Nektar Therapeutics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<ul type=\"disc\">\n<li>H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference on <span class=\"xn-chron\">Thursday, March 27, 2025<\/span> at <span class=\"xn-chron\">2:00 p.m. Eastern Time<\/span> \/ <span class=\"xn-chron\">11:00 a.m. Pacific Time<\/span> \u2013 webcast link\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4386813-1&amp;h=1594194593&amp;u=https%3A%2F%2Fjourney.ct.events%2Fview%2F16c4f6ae-83a5-4a4c-9060-16cb4c1da566&amp;a=here\" target=\"_blank\" rel=\"nofollow\">here<\/a><\/li>\n<\/ul>\n<p>The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website:\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4386813-1&amp;h=1528376000&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295470-1%26h%3D2008999995%26u%3Dhttps%253A%252F%252Fir.nektar.com%252Fevents-and-presentations%252Fevents%26a%3Dhttps%253A%252F%252Fir.nektar.com%252Fevents-and-presentations%252Fevents&amp;a=https%3A%2F%2Fir.nektar.com%2Fevents-and-presentations%2Fevents\" target=\"_blank\" rel=\"nofollow\">https:\/\/ir.nektar.com\/events-and-presentations\/events<\/a>. A replay of the presentation will be available for 30 days.<\/p>\n<p>If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative.<\/p>\n<p>\n        <b>About Nektar Therapeutics<\/b>\n      <\/p>\n<p>Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar&#8217;s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase <span class=\"xn-money\">2b<\/span> clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar&#8217;s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system&#8217;s natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in <span class=\"xn-location\">San Francisco, California<\/span>. For further information, visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4386813-1&amp;h=2078624660&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295470-1%26h%3D1288677133%26u%3Dhttp%253A%252F%252Fwww.nektar.com%252F%26a%3Dwww.nektar.com&amp;a=www.nektar.com\" target=\"_blank\" rel=\"nofollow\">www.nektar.com<\/a>\u00a0and follow Nektar on\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4386813-1&amp;h=328582151&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4295470-1%26h%3D274072813%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4188942-1%2526h%253D2235361742%2526u%253Dhttps%25253A%25252F%25252Fwww.linkedin.com%25252Fcompany%25252Fnektar-therapeutics%25252F%2526a%253DLinkedIn%26a%3DLinkedIn&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>Contact:<\/b>\n      <\/p>\n<p>\n        <b>For Investors:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Corey Davis<\/span>, Ph.D.<br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:cdavis@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow\">cdavis@lifesciadvisors.com<\/a> \u00a0<br \/>212-915-2577<\/p>\n<p>Ahu Demir, Ph.D.<br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:ademir@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow\">ademir@lifesciadvisors.com<\/a><br \/>212-915-3820<\/p>\n<p>\n        <b>For Media:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Madelin Hawtin<\/span><br \/>\n        <br \/>LifeSci Communications<br \/>603-714-2638<br \/><a href=\"mailto:mhawtin@lifescicomms.com\" target=\"_blank\" rel=\"nofollow\">mhawtin@lifescicomms.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF45003&amp;sd=2025-03-20\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/nektar-therapeutics-to-participate-in-the-hc-wainwright-3rd-annual-autoimmune--inflammatory-disease-virtual-conference-302407356.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/nektar-therapeutics-to-participate-in-the-hc-wainwright-3rd-annual-autoimmune&#8211;inflammatory-disease-virtual-conference-302407356.html<\/a><\/p>\n<p>SOURCE  Nektar Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF45003&amp;Transmission_Id=202503201800PR_NEWS_USPR_____SF45003&amp;DateId=20250320\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN FRANCISCO , March 20, 2025 \/PRNewswire\/ &#8212; Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time \/ 11:00 a.m. Pacific Time \u2013 webcast link\u00a0here The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website:\u00a0https:\/\/ir.nektar.com\/events-and-presentations\/events. A replay of the presentation will be available for 30 days. If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828355","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN FRANCISCO , March 20, 2025 \/PRNewswire\/ &#8212; Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time \/ 11:00 a.m. Pacific Time \u2013 webcast link\u00a0here The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website:\u00a0https:\/\/ir.nektar.com\/events-and-presentations\/events. A replay of the presentation will be available for 30 days. If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. &hellip; Continue reading &quot;Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-20T22:03:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference\",\"datePublished\":\"2025-03-20T22:03:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\"},\"wordCount\":335,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/nektar_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\",\"name\":\"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/nektar_logo.jpg\",\"datePublished\":\"2025-03-20T22:03:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/nektar_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/nektar_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","og_description":"PR Newswire SAN FRANCISCO , March 20, 2025 \/PRNewswire\/ &#8212; Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time \/ 11:00 a.m. Pacific Time \u2013 webcast link\u00a0here The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website:\u00a0https:\/\/ir.nektar.com\/events-and-presentations\/events. A replay of the presentation will be available for 30 days. If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. &hellip; Continue reading \"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-20T22:03:43+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference","datePublished":"2025-03-20T22:03:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"},"wordCount":335,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/","name":"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg","datePublished":"2025-03-20T22:03:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/nektar_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nektar-therapeutics-to-participate-in-the-h-c-wainwright-3rd-annual-autoimmune-inflammatory-disease-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune &amp; Inflammatory Disease Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828355"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828355\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}